


TOP ↑
Industry
NEWS

***BUSY WEEK?** Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

1. [Lonza Completes \\$5.5-Billion Acquisition of Capsugel](#)

Lonza has completed its acquisition of Capsugel, a provider of dosage forms, from the private equity forum, KKR, for \$5.5 billion in cash, including refinancing of existing Capsugel debt of approximately \$2 billion. [Read More](#)

2. [Stada Appoints Interim CEO, CFO Following Failed \\$5.6-Billion Buyout](#)

Following a failed \$5.6-billion acquisition bid by two investment firms that did not gain shareholder approval, Stada Arzneimittel AG, a Bad Vilbel, Germany-based generic and over-the-counter drug company, is undergoing a change in executive leadership with the appointment of an interim CEO and CFO. [Read More](#)

3. [Celgene, BeiGene in Immuno-Oncology Deal Worth Up to \\$1 Billion-Plus](#)

Celgene has formed a strategic collaboration with BeiGene, a Beijing headquartered clinical-stage biopharmaceutical company focused on immuno-oncology, in a deal worth up to more than \$1-billion. The deal includes development and commercialization of BeiGene's investigational PD-1 inhibitor as well as Celgene taking a 5.9% equity stake in BeiGene and BeiGene acquiring Celgene's operations in China. [Read More](#)

4. [Daiichi Sankyo Ends Development of Biosimilar for Manufacturing Issues](#)

Daiichi Sankyo has decided to discontinue the development in Japan of an investigational etanercept biosimilar in rheumatoid arthritis conducted with the US company, Coherus BioSciences, due to manufacturing issues. [Read More](#)

5. [Bayer Invests in Animal-Health Production](#)

Bayer plans to invest approximately EUR 92 million (\$105 million) into the further development of its production site for animal-health products in Kiel, Germany. [Read More](#)

6. [Sun Pharma, Samsung Biologics Enter \\$55.5-Million Manufacturing Deal](#)

Sun Pharmaceutical Industries and Samsung BioLogics, a contract biologics manufacturer, have formed a \$55.5-million strategic long-term manufacturing agreement for tildrakizumab, an investigational drug for treating moderate-to-severe plaque psoriasis. [Read More](#)

7. [Pacira Ends Production of Sterile Injectable](#)

Pacira Pharmaceuticals, a specialty pharmaceutical company, has discontinued all future production of DepoCyt/DepoCyte, a sterile, injectable suspension of the antimetabolite, cytarabine, in the US, Canada, and the European Union, due to persistent technical issues specific to the product's manufacturing process. [Read More](#)

8. [FDA Issues Draft Guidance on Product Identifiers for Serialization](#)

The FDA has issued draft guidance delaying enforcement of certain product identifier requirements under the Drug Supply Chain Security Act (DSCSA). The DSCSA was signed into law in November 2013 and outlined steps to build an electronic, interoperable system by November 2023 to identify and trace prescription drugs as they are distributed within the US. [Read More](#)

9. [CSL's Seqirus Produces Cell-Based Influenza Vaccine at Commercial Scale](#)

Seqirus, a developer and manufacturer of influenza vaccines and part of the Australian pharmaceutical company, CSL Limited, has produced a cell-based influenza vaccine at commercial scale at its manufacturing facility in Holly Springs, North Carolina. [Read More](#)

10. [Novartis Signs Supply Pact Up to \\$100 Million for CAR T Therapies](#)

Novartis has signed an agreement with Oxford BioMedica, a company specializing in gene and cell therapy manufacturing, for the commercial and clinical supply of lentiviral vectors used to generate chimeric antigen receptor T cell (CAR T) products, including CTL019 (tisagenlecleucel), Novartis' lead CAR T therapy. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!***

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by mailmanager@dcat.org